VanEck Pharmaceutical ETF
PPH
52 hedge funds and large institutions have $99.9M invested in VanEck Pharmaceutical ETF in 2015 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 21 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
6.01% less ownership
Funds ownership: 32.9% → 26.88% (-6%)
7% less capital invested
Capital invested by funds: $108M → $99.9M (-$7.72M)
10% less funds holding
Funds holding: 58 → 52 (-6)
33% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 21
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$5.95M |
| 2 |
SCM
Stuyvesant Capital Management
Armonk,
New York
|
+$2.07M |
| 3 |
Morgan Stanley
New York
|
+$1.91M |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$1.5M |
| 5 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$13.7M |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$3.33M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.71M |
| 4 |
ACM
Aviance Capital Management
Sarasota,
Florida
|
-$2.54M |
| 5 |
SG Americas Securities
New York
|
-$2.54M |
PPH Hedge Fund Activity: Q1 2015 in Review
52 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2015, worth a combined $99.9M — down 7.2% from $108M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PPH and 4 opened new positions — a net loss of 5 holders — while 21 trimmed existing stakes and 14 added.
The largest buyer was Goldman Sachs, adding an estimated $5.95M. The largest seller was Clal Insurance, exiting entirely with an estimated $13.7M sold.
- 52 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2015, down from 58 in Q4 2014.
- Funds reported $99.9M of VanEck Pharmaceutical ETF stock for Q1 2015, down 7.2% quarter-over-quarter.
- 4 funds opened new VanEck Pharmaceutical ETF positions in Q1 2015 and 9 closed out, a net change of -5 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2015 was Goldman Sachs, an estimated $5.95M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2015 was Clal Insurance, an estimated $13.7M sold.
Based on aggregated 13F filings for Q1 2015.